Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Babadaei, M.M.N.; Hasan, A.; Vahdani, Y.; Bloukh, S.H.; Sharifi, M.; Kachooei, E.; Haghighat, S.; Falahati, M.
    Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase (2020), J. Biomol. Struct. Dyn., 2020, 1-9 .
    View publication on PubMedView publication on EuropePMC

Inhibitors

EC Number Inhibitors Comment Organism Structure
2.7.7.48 remdesivir
-
 Severe acute respiratory syndrome coronavirus 2

Natural Substrates/ Products (Substrates)

EC Number Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
2.7.7.48 nucleoside triphosphate + RNAn Severe acute respiratory syndrome coronavirus 2
-
 diphosphate + RNAn+1
-
 ?

Organism

EC Number Organism UniProt Comment Textmining
2.7.7.48 Severe acute respiratory syndrome coronavirus 2 P0DTD1 replicase polyprotein 1ab; SARS-CoV-2
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.7.7.48 nucleoside triphosphate + RNAn
-
 Severe acute respiratory syndrome coronavirus 2 diphosphate + RNAn+1
-
 ?

Synonyms

EC Number Synonyms Comment Organism
2.7.7.48 RDRP
-
 Severe acute respiratory syndrome coronavirus 2
2.7.7.48 RNA-dependent RNA polymerase
-
 Severe acute respiratory syndrome coronavirus 2